GlassScriptPhysician profile
Heather Yeckes Rodin
NPI 1740214840
$26,587.27
in general payments reported to CMS, 2019-2025
68 companies · $8,096 in 2025
The $8,096 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,955 · 2020: $2,402 · 2021: $2,123 · 2022: $2,237 · 2023: $3,431 · 2024: $5,343 · 2025: $8,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $4,830 · Long Term Medical Supply Or Device Loan: $881 · Education: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,904.86 |
| Consulting Fee | $4,830.00 |
| Long Term Medical Supply Or Device Loan | $880.93 |
| Education | $253.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,436.77 | 2019-2025 | Enhertu, Lynparza, Calquence |
| E.R. Squibb & Sons, L.L.C. | $2,895.41 | 2019-2025 | Opdualag, Reblozyl |
| Pfizer INC. | $1,997.92 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,732.51 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,134.12 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Genzyme Corporation | $1,054.24 | 2019-2025 | |
| Amgen INC. | $812.21 | 2019-2023 | Blincyto, Kyprolis |
| Seagen INC. | $790.17 | 2019-2025 | Adcetris, Tukysa, Padcev |
| Janssen Biotech, INC. | $782.40 | 2019-2025 | Darzalex, Rybrevant, Tecvayli |
| Daiichi Sankyo INC. | $754.25 | 2020-2025 | Enhertu, Datroway |
| Lilly USA, LLC | $727.44 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Genentech USA, INC. | $723.65 | 2019-2024 | Tecentriq, Polivy, Columvi |
| Incyte Corporation | $695.44 | 2020-2025 | Jakafi, Monjuvi, Pemazyre |
| Regeneron Healthcare Solutions, INC. | $667.10 | 2021-2025 | Libtayo |
| Glaxosmithkline, LLC. | $663.38 | 2020-2025 | Zejula, Ojjaara, Jemperli |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $608.85 | 2024-2025 | Xt Cdx |
| Abbvie INC. | $520.84 | 2019-2025 | Venclexta |
| Puma Biotechnology, INC. | $514.53 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $462.48 | 2019-2025 | Fruzaqla, Ninlaro, Iclusig |
| Asd Specialty Healthcare, LLC | $392.50 | 2023-2025 | |
| Astellas Pharma US INC | $381.84 | 2019-2025 | Xtandi, Vyloy, Padcev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.45 | 2019-2025 | |
| Eisai INC. | $334.86 | 2019-2025 | |
| Celltrion USA INC. | $294.87 | 2023 | Vegzelma |
| Gilead Sciences, INC. | $292.04 | 2019-2025 | Trodelvy |
| Celgene Corporation | $283.17 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Kite Pharma, INC. | $270.70 | 2020-2025 | Yescarta |
| Beigene USA, INC. | $202.08 | 2020-2025 | Brukinsa, Tevimbra |
| Beone Medicines USA, INC. | $189.78 | 2025 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $186.91 | 2019-2025 | |
| Mirati Therapeutics, INC. | $172.08 | 2023 | Krazati |
| Karyopharm Therapeutics INC. | $168.41 | 2020-2025 | Xpovio |
| Coherus Oncology, INC. | $166.03 | 2020-2022 | |
| Stemline Therapeutics INC. | $153.98 | 2025 | Orserdu |
| Jazz Pharmaceuticals INC. | $132.89 | 2020-2025 | |
| Array Biopharma INC | $130.60 | 2019-2025 | Mektovi, Lorbrena, Braftovi |
| Alexion Pharmaceuticals, INC. | $127.75 | 2019-2025 | Ultomiris |
| Dova Pharmaceuticals | $127.54 | 2019-2021 | |
| Sobi, INC | $124.33 | 2022-2023 | |
| Caris Mpi, INC. | $117.53 | 2025 | Mi Cancer Seek |
| Ipsen Biopharmaceuticals, INC | $115.31 | 2019-2025 | Onivyde, Somatuline Depot, Tazverik |
| Tesaro, INC. | $94.97 | 2019 | |
| Exelixis INC. | $87.59 | 2019-2024 | Cabometyx |
| Pharmacyclics LLC, An Abbvie Company | $78.83 | 2021-2023 | Imbruvica |
| Amag Pharmaceuticals, INC. | $77.98 | 2019 | |
| Aveo Pharmaceuticals, INC. | $61.35 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $45.44 | 2024-2025 | Alymsys, Neupogen, Avastin |
| Accord Healthcare, INC. | $45.09 | 2023 | |
| Servier Pharmaceuticals LLC | $44.68 | 2023-2025 | |
| Taiho Oncology, INC. | $41.19 | 2025 | |
| Emd Serono, INC. | $40.81 | 2024 | |
| Verastem, INC. | $37.70 | 2019 | |
| Azurity Pharmaceuticals, INC. | $28.60 | 2025 | Danziten |
| Aurobindo Pharma USA, INC. | $27.46 | 2019-2020 | |
| Geron Corporation | $25.40 | 2025 | Rytelo |
| Intrinsiq Specialty Solutions, INC. | $24.88 | 2024 | |
| Myovant Sciences INC. | $19.34 | 2021 | |
| Genmab U.S., INC. | $18.72 | 2024 | Epkinly |
| Cardinal Health 108 LLC | $18.37 | 2019 | |
| Morphosys, US INC. | $18.03 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $16.90 | 2019 | |
| Agios Pharmaceuticals, INC. | $15.86 | 2020 | |
| Acceleron Pharma, INC. | $15.53 | 2021 | |
| Advanced Accelerator Applications | $14.07 | 2020 | |
| Allergan, INC. | $13.12 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Yeckes Rodin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.